862 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
The Zacks Analyst Blog Highlights: Bank of America, Merck, Netflix, IBM and The Bank of New York Mellon http://www.zacks.com/stock/news/348753/the-zacks-analyst-blog-highlights-bank-of-america-merck-netflix-ibm-and-the-bank-of-new-york-mellon?cid=CS-ZC-FT-348753 Jan 22, 2019 - The Zacks Analyst Blog Highlights: Bank of America, Merck, Netflix, IBM and The Bank of New York Mellon
Merck's Partner Gets FDA Nod for Herceptin Biosimilar http://www.zacks.com/stock/news/348729/mercks-partner-gets-fda-nod-for-herceptin-biosimilar?cid=CS-ZC-FT-348729 Jan 21, 2019 - Merck's (MRK) partner, Samsung Bioepis Co. gets FDA approval for Ontruzant, a Herceptin Biosimilar.
Sanofi's (SNY) Influenza Vaccine Gets FDA Approval for Kids http://www.zacks.com/stock/news/349470/sanofis-sny-influenza-vaccine-gets-fda-approval-for-kids?cid=CS-ZC-FT-349470 Jan 24, 2019 - Sanofi's (SNY) influenza vaccine, Fluzone Quadrivalent (0.5mL dose), gains an FDA nod for treating children in six to 35-month age group.
Dow 30 Stock Roundup: UTX, TRV, PG, JNJ Earnings Impress, IBM Revenues Decline Y/Y http://www.zacks.com/stock/news/349651/dow-30-stock-roundup-utx-trv-pg-jnj-earnings-impress-ibm-revenues-decline-y-y?cid=CS-ZC-FT-349651 Jan 25, 2019 - The index traversed an eventful, yet holiday-shortened week.
Amgen/Allergan's Rituxan Biosimilar Meets Goal in Phase III http://www.zacks.com/stock/news/349758/amgen-allergans-rituxan-biosimilar-meets-goal-in-phase-iii?cid=CS-ZC-FT-349758 Jan 25, 2019 - Amgen (AMGN) along with partner Allergan reports upbeat top-line data from a phase I/III study on ABP 798, a biosimilar candidate of Roche???s Rituxan. The program achieves the primary endpoint.
Why Merck (MRK) Could Beat Earnings Estimates Again http://www.zacks.com/stock/news/350358/why-merck-mrk-could-beat-earnings-estimates-again?cid=CS-ZC-FT-350358 Jan 29, 2019 - Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stock Market News For Feb 4, 2019 http://www.zacks.com/stock/news/351843/stock-market-news-for-feb-4-2019?cid=CS-ZC--351843 Feb 04, 2019 - Markets closed mostly in the green on Friday after the release of stellar economic data boosted investor sentiment.
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-352085 Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark http://www.zacks.com/stock/news/353400/seattle-genetics-sgen-q4-loss-widens-revenues-top-mark?cid=CS-ZC-FT-353400 Feb 08, 2019 - Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.
Merck's Keytruda Gets FDA Priority Review for Head/Neck Cancer http://www.zacks.com/stock/news/353843/mercks-keytruda-gets-fda-priority-review-for-head-neck-cancer?cid=CS-ZC-FT-353843 Feb 12, 2019 - Merck's (MRK) supplemental biologics license application for Keytruda receives a priority review from the FDA for the first-line treatment of patients with recurrent/metastatic head and neck cancer.
<<<Page 81>